<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130125</url>
  </required_header>
  <id_info>
    <org_study_id>LG-IMHOS001</org_study_id>
    <nct_id>NCT05130125</nct_id>
  </id_info>
  <brief_title>Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer</brief_title>
  <official_title>Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer After Ovarian Hyperstimulation (Administration of rFSH or HP-hMG Alone or Co-administration of rFSH and HP-hMG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, retrospective cohort observational study to evaluate the effectiveness and&#xD;
      safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of&#xD;
      rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, retrospective cohort observational study to evaluate the effectiveness and&#xD;
      safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of&#xD;
      rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG) to infertile female patients&#xD;
      undergoing assisted reproductive technology to controlled ovarian hyperstimulation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Oocytes</measure>
    <time_frame>average of 14 days</time_frame>
    <description>Counting number of Oocytes</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>fresh embryo</arm_group_label>
    <description>fresh embryo transfer after ovarian hyperstimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>frozen embryo</arm_group_label>
    <description>frozen embryo transfer after ovarian hyperstimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH</intervention_name>
    <description>rFSH or HP-hMG or rFSH and HP-hMG</description>
    <arm_group_label>fresh embryo</arm_group_label>
    <arm_group_label>frozen embryo</arm_group_label>
    <other_name>HP-hMG</other_name>
    <other_name>rFSH and HP-hMG</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        infertile female patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First IVF-ET cycle patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Poor ovarian responder&#xD;
&#xD;
        - At least two of the following three features must be present: (i) Advanced maternal age&#xD;
        (≥ 40 years) or any other risk factor for Poor ovarian response (POR); (ii) A previous POR&#xD;
        (≤ 3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve&#xD;
        test (i.e. AFC &lt; 5-7 follicles or AMH &lt; 0.5-1.1 ng/mL)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieun Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cha medical center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujung Lee</last_name>
    <phone>82-26987-4287</phone>
    <email>yujunglee@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Fertility Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieun Shin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

